Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Sotorasib

FDA-approved product (tablet, oral), marketed as Lumakras.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Sotorasib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Neoplasm
  • Non-small cell lung carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antineoplastic agents
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against K. pneumoniae, MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA70.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli47.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae51.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis71.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Sotorasib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Sotorasib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Ladarixin With Sotorasib in Advanced NSCLC

    NCT05815173 · start 2023-08-01

    Registered record
    Registry ID
    NCT05815173
    Conditions
    Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation
    Interventions
    Sotorasib; Ladarixin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2023-08-01
    Completion
    2027-08
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Non-small Cell Lung Cancer With KRAS G12C Mutation
    InterventionSotorasib; Ladarixin
    PhasePhase 1
    Registry statusRecruiting

  • Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)

    NCT05845450 · start 2023-05-11

    Registered record
    Registry ID
    NCT05845450
    Conditions
    Colorectal Cancer; Resectable Colorectal Carcinoma
    Interventions
    Trastuzumab deruxtecan; Durvalumab; Panitumumab; Botensilimab; Balstilimab; Sotorasib; Vorbipiprant; Nivolumab; Amivantamab; Botensilimab; Balstilimab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2023-05-11
    Completion
    2028-05
    Enrolment
    197

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Cancer; Resectable Colorectal Carcinoma
    InterventionTrastuzumab deruxtecan; Durvalumab; Panitumumab; Botensilimab +7 more
    PhasePhase 2
    Registry statusRecruiting

  • Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

    NCT05564377 · start 2023-04-07

    Registered record
    Registry ID
    NCT05564377
    Conditions
    Advanced Malignant Solid Neoplasm; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Locally Advanced Malignant Solid Neoplasm; Malignant Female Reproductive System Neoplasm; Metastatic HER2-Negative Breast Carcinoma; Metastatic Malignant Solid Neoplasm; Recurrent Endometrial Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Malignant Female Reproductive System Neoplasm; Recurrent Malignant Solid Neoplasm; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Unresectable HER2-Negative Breast Carcinoma; Unresectable Malignant Solid Neoplasm
    Interventions
    Alpelisib; Binimetinib; Biopsy Procedure; Biospecimen Collection; Bone Marrow Aspiration; Bone Marrow Biopsy; Bone Scan; Computed Tomography; Echocardiography Test; Fluorouracil; Fulvestrant; Ipatasertib; Leucovorin; Magnetic Resonance Imaging; Multigated Acquisition Scan; Mutation Carrier Screening; Neratinib Maleate; Nilotinib Hydrochloride Monohydrate; Olaparib; Oxaliplatin; Paclitaxel; Palbociclib; Panitumumab; Positron Emission Tomography; Selumetinib Sulfate; Sotorasib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2023-04-07
    Completion
    2030-07-01
    Enrolment
    2,900

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Malignant Solid Neoplasm; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Locally Advanced Malignant Solid Neoplasm +11 more
    InterventionAlpelisib; Binimetinib; Biopsy Procedure; Biospecimen Collection +22 more
    PhasePhase 2
    Registry statusRecruiting

  • Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With Mutated KRAS p.G12C

    NCT05631249 · start 2022-12-13

    Registered record
    Registry ID
    NCT05631249
    Conditions
    KRAS P.G12C; Non Small Cell Lung Cancer
    Interventions
    Sotorasib 120Mg Tab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2022-12-13
    Completion
    2027-12-12
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKRAS P.G12C; Non Small Cell Lung Cancer
    InterventionSotorasib 120Mg Tab
    PhasePhase 2
    Registry statusRecruiting

  • VIC-1911 Monotherapy in Combination With Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer

    NCT05374538 · start 2022-11-09

    Registered record
    Registry ID
    NCT05374538
    Conditions
    Non-small Cell Lung Cancer
    Interventions
    VIC-1911; sotorasib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2022-11-09
    Completion
    2023-08-26
    Enrolment
    3

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-small Cell Lung Cancer
    InterventionVIC-1911; sotorasib
    PhasePhase 1
    Registry statusTerminated

  • Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer

    NCT05251038 · start 2022-09-13

    Registered record
    Registry ID
    NCT05251038
    Conditions
    Pancreatic Cancer; Unresectable Pancreatic Cancer; Metastatic Pancreatic Cancer; KRAS P.G12C
    Interventions
    Sotorasib; Liposomal Irinotecan (nal-IRI); 5 Fluorouracil (5FU); Leucovorin (LV); Gemcitabine (GEM); Nab paclitaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Withdrawn
    Start
    2022-09-13
    Completion
    2023-01-31
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPancreatic Cancer; Unresectable Pancreatic Cancer; Metastatic Pancreatic Cancer; KRAS P.G12C
    InterventionSotorasib; Liposomal Irinotecan (nal-IRI); 5 Fluorouracil (5FU); Leucovorin (LV) +2 more
    PhasePhase 1 / Phase 2
    Registry statusWithdrawn

  • A Study to Evaluate the Impact of Omeprazole on the Pharmacokinetics of Sotorasib Co-administered With an Acidic Beverage in Healthy Volunteers

    NCT05497557 · start 2022-07-14

    Registered record
    Registry ID
    NCT05497557
    Conditions
    Healthy Volunteers
    Interventions
    Omeprazole; Sotorasib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2022-07-14
    Completion
    2022-09-08
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionOmeprazole; Sotorasib
    PhasePhase 1
    Registry statusCompleted

  • SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation

    NCT05480865 · start 2022-07-06

    Registered record
    Registry ID
    NCT05480865
    Conditions
    Solid Tumor, Adult; Metastatic Solid Tumor; Metastatic NSCLC; Non Small Cell Lung Cancer
    Interventions
    BBP-398; sotorasib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2022-07-06
    Completion
    2024-08-22
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSolid Tumor, Adult; Metastatic Solid Tumor; Metastatic NSCLC; Non Small Cell Lung Cancer
    InterventionBBP-398; sotorasib
    PhasePhase 1
    Registry statusTerminated

  • A Phase I/II Study of AMG 510 in Combination With MVASI in Patients With Advanced, Unresectable or Metastatic KRAS G12C Mutant NSCLC With Asymptomatic Brain Metastasis

    NCT05180422 · start 2022-06-15

    Registered record
    Registry ID
    NCT05180422
    Conditions
    Non Small Cell Lung Cancer
    Interventions
    AMG 510; MVASI
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Withdrawn
    Start
    2022-06-15
    Completion
    2023-01-31
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon Small Cell Lung Cancer
    InterventionAMG 510; MVASI
    PhasePhase 1 / Phase 2
    Registry statusWithdrawn

  • Sotorasib in Advanced KRASG12C-mutated Non-small Cell Lung Cancer Patients With Comorbidities

    NCT05311709 · start 2022-05-30

    Registered record
    Registry ID
    NCT05311709
    Conditions
    Lung Cancer; NSCLC, Stage III; NSCLC Stage IV; Lung Cancer Stage IV; Mutation; Cancer; Cancer, Lung
    Interventions
    sotorasib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2022-05-30
    Completion
    2025-03-01
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLung Cancer; NSCLC, Stage III; NSCLC Stage IV; Lung Cancer Stage IV +3 more
    Interventionsotorasib
    PhasePhase 2
    Registry statusUnknown

  • A Study in Healthy Volunteers to Compare the Pharmacokinetics of Sotorasib Administered as 1 or 2 Tablets

    NCT05327491 · start 2022-03-21

    Registered record
    Registry ID
    NCT05327491
    Conditions
    Healthy Participants
    Interventions
    Sotorasib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2022-03-21
    Completion
    2022-07-17
    Enrolment
    146

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Participants
    InterventionSotorasib
    PhasePhase 1
    Registry statusCompleted

  • Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapy

    NCT05398094 · start 2022-03-21

    Registered record
    Registry ID
    NCT05398094
    Conditions
    Non-small Cell Lung Cancer Stage III; KRAS P.G12C
    Interventions
    Sotorasib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2022-03-21
    Completion
    2028-12-31
    Enrolment
    19

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-small Cell Lung Cancer Stage III; KRAS P.G12C
    InterventionSotorasib
    PhasePhase 2
    Registry statusRecruiting

  • Tarlox and Sotorasib in Patients With KRAS G12C Mutations

    NCT05313009 · start 2022-03-07

    Registered record
    Registry ID
    NCT05313009
    Conditions
    Non-Small Cell Lung Cancer
    Interventions
    Sotorasib and Tarloxotinib; Sotorasib and Tarloxotinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2022-03-07
    Completion
    2023-12-31
    Enrolment
    5

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Small Cell Lung Cancer
    InterventionSotorasib and Tarloxotinib; Sotorasib and Tarloxotinib
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • RW Efficacy of Sotorasib in KRAS G12C-mutated Metastatic NSCLC

    NCT05273047 · start 2022-03-01

    Registered record
    Registry ID
    NCT05273047
    Conditions
    Nsclc; KRAS P.G12C
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2022-03-01
    Completion
    2024-12-31
    Enrolment
    458

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNsclc; KRAS P.G12C
    InterventionNot recorded
    PhaseNot recorded
    Registry statusUnknown

  • A Study of Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a KRAS p.G12C Mutation in Need of First-line Treatment

    NCT04933695 · start 2022-01-28

    Registered record
    Registry ID
    NCT04933695
    Conditions
    Non-small Cell Lung Cancer
    Interventions
    Sotorasib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2022-01-28
    Completion
    2025-05-28
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-small Cell Lung Cancer
    InterventionSotorasib
    PhasePhase 2
    Registry statusTerminated